Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study
Authors' conclusion
In conclusion, in addition to the known anti-cancer benefits of adjuvant zoledronate, there are likely to be positive, lasting benefits in BMD and bone turnover.
Study context
- Population
- Recurrence-free women with early breast cancer who had completed the AZURE trial within the previous 3 mo, 20 UK AZURE sites
- Participants
- 224 women
- Comparison
- Prior adjuvant zoledronate vs control
- Zoledronaten = 120
- Controln = 104reference
Methodological detailsmulticentre, 5-yr follow-up after trial completion
- Multicentre
- 5-yr follow-up after trial completion
Primary result
As reported in the abstract
Lumbar spine standardized bone mineral density (BMD) (sBMD) · sub-study entry
P < 0.0001
Further findings
| Outcome | P value |
|---|---|
| BTMs after completing zoledronate · sub-study entryZoledronate vs Control · lower with Zoledronate | both P < .00001 |
| BTMs after completing zoledronate · sub-study entryZoledronate vs Control · lower with Zoledronate | P < 0.00001 |
| BTMs after completing zoledronate · sub-study entryZoledronate vs Control · lower with Zoledronate | P = 0.0001 |
Bone turnover markers (BTMs) after completing zoledronate · sub-study entry
- Some offset of bone turnover inhibition in the 12 mo after completing zoledronate; thereafter all BTMs remained suppressed vs control during 60 mo
Original publication
Prolonged bone health benefits for breast cancer patients following adjuvant bisphosphonate therapy: the BoHFAB study. J Bone Miner Res. Published 4 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →